Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EBT: 2020-2024

Historic EBT for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$241.6 million.

  • NewAmsterdam Pharma Co N.V's EBT fell 332.51% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.57% down from last year.
  • NewAmsterdam Pharma Co N.V's EBT amounted to -$241.6 million in FY2024, which was down 36.57% from -$176.9 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's EBT peaked at -$6.6 million during FY2020, and registered a low of -$241.6 million during FY2024.
  • Moreover, its 3-year median value for EBT was -$176.9 million (2023), whereas its average is -$147.0 million.
  • Per our database at Business Quant, NewAmsterdam Pharma Co N.V's EBT surged by 45.83% in 2022 and then tumbled by 681.61% in 2023.
  • Yearly analysis of 5 years shows NewAmsterdam Pharma Co N.V's EBT stood at -$6.6 million in 2020, then plummeted by 536.57% to -$41.8 million in 2021, then surged by 45.83% to -$22.6 million in 2022, then slumped by 681.61% to -$176.9 million in 2023, then slumped by 36.57% to -$241.6 million in 2024.